We do know that trials need to be registered or, I believe, confirmatory before any potential milestone payout can occur. Seems all they are doing is exploratory studies at this point. Such studies can take years according to a reliable source. It’s tough to get excited about any milestone prospects. But I’m sure we don’t see the whole picture.
True, many don't know what many don't know ...but we do know that a very, improbable, irregular list of events occurred, as some impossible list of events have amassed (taken as a whole...) from the beginnings of the late Dr Thorpe's work with the IP assets from Bavi to Betabodies and all in between.
Further, SEC trade filings from over the years will prove things that may not go public...right up to "EXACT" trades of transfer of shares that were pointed out last quarter ....again, impossible to have happened unless multiple hedge funds were working together
Now...taken all these events and bringing us to some midlife crisis that will fall upon some, because Apollo Group Management will be tied to some events as subsidiary MidCap Financial listed under IP assets...but if they listen to some here they should just give up those assets...eh? lol
MidCap Funding III ties to MidCap Financial and is managed by Apollo Capital Management, L.P., a subsidiary of Apollo Global Management, LLC, pursuant to an investment management ...
____
Constructs binding to phosphatidylserine and their use in disease treatment
Abstract
Disclosed are new phosphatidylserine binding constructs with surprising combinations of properties, and a range of diagnostic and therapeutic conjugates thereof. The new constructs effectively bind phosphatidylserine targets in disease and enhance their destruction, and can also specifically deliver attached imaging or therapeutic agents to the disease site. Also disclosed are methods of using the new construct compositions, therapeutic conjugates and combinations thereof in tumor vasculature targeting, cancer diagnosis and treatment, and for treating viral infections and other diseases. Images (28)
Classifications
C07K14/775 Apolipopeptides View 20 more classifications US20060228299A1 United States Download PDF Find Prior Art Similar
Inventor Philip Thorpe Troy Luster Steven King
Current Assignee MIDCAP FUNDING III LLC Peregrine Pharmaceuticals Inc University of Texas System
Worldwide applications 2006 WO NZ DK AU ES SI EP US JP CN CA CN SG CN 2007 IL 2012 JP 2014 HK 2015 US HK 2016 US Application US11/339,392 events 2005-01-24
Priority to US64633305P 2006-01-24
Application filed by Peregrine Pharmaceuticals Inc, University of Texas System
2006-10-12 Publication of US20060228299A1
2015-02-17 Publication of US8956616B2
2015-02-17 Application granted
2019-11-11 Application status is Active
2027-12-10 Adjusted expiration ______
I admit, information overload is what some will see at first sight....but others see a clear, very well designed plan...to hijack the IP and science behind Billions of $$$ of required patents many will require to pay licensing fees
______
Eli Lilly had most recently went public in ways....and is it a coincidence for them just hiring Brownstein Hyatt Farber Schrek just in last 24 hours? I noticed ex Merck now Brownstein "Jerome Murray landed at Brownstein as well just in Dec 17, 2018
____
Nov 11, 2019
Eli Lilly hires Brownstein Hyatt By THEODORIC MEYER 11/11/2019 02:30 PM EST Presented by REALTOR® With David Beavers and Daniel Lippman
NEW BUSINESS: Eli Lilly has added Brownstein Hyatt Farber Schreck to its lineup of Washington lobbying firms. Zach Pfister, Marc Lampkin, Emily Felder, Nadeam Elshami and Brian Wildwill represent the pharmaceutical giant. Elshami is a former chief of staff to House Speaker Nancy Pelosi. Eli Lilly has spent nearly $5.1 million on Washington lobbying so far this year, according to disclosure filings, and also retains